"Janus Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit JANUS KINASES.
| Descriptor ID |
D000075242
|
| MeSH Number(s) |
D27.505.519.389.755.500
|
| Concept/Terms |
Janus Kinase Inhibitors- Janus Kinase Inhibitors
- Inhibitors, Janus Kinase
- Kinase Inhibitors, Janus
- JAK Inhibitors
- Inhibitors, JAK
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase Inhibitors".
This graph shows the total number of publications written about "Janus Kinase Inhibitors" by people in this website by year, and whether "Janus Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 6 | 0 | 6 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase Inhibitors" by people in Profiles.
-
Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 Nov 04; 30(11):2057-2063.
-
Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024 May; 11(5):e383-e389.
-
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
-
JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.
-
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis. 2023 09 01; 29(9):1370-1379.
-
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.
-
The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Jul-Dec; 19(9):1075-1089.
-
Looking from the Past to the Future: How Janus Kinase Inhibitors Have Altered the Therapy of Ulcerative Colitis. Dig Dis Sci. 2023 06; 68(6):2248-2251.
-
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 06; 18(3):41-55.
-
Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 12; 163(6):1555-1568.